Exact Sciences Corporation (EXAS) Earnings Call Analysis
NASDAQ · Healthcare · Diagnostics & Research
Earnings Reports
-
Exact Sciences (EXAS) Q3 2025: Screening Revenue Jumps 22% as Cologuard Plus Adoption Accelerates
November 04, 2025
-
Exact Sciences (EXAS) Q2 2025: Screening Revenue Climbs 18% as Cologuard Plus and Freenome Deal Reshape Portfolio
August 07, 2025
-
Exact Sciences (EXAS) Q1 2025: Cologuard Plus Drives 40% Reduction in False Positives, Accelerating Screening Adoption
July 04, 2025